Physician profile
Joel E Max
NPI 1760431852
$2,365.20
in general payments reported to CMS, 2019-2025
20 companies · $4.05 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $231 · 2021: $476 · 2022: $464 · 2023: $269 · 2024: $371 · 2025: $4.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.15 |
| Education | $290.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $503.07 | 2019-2023 | |
| Janssen Biotech, INC. | $440.83 | 2022-2024 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $407.25 | 2019-2022 | |
| Abbvie INC. | $166.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $151.99 | 2019-2021 | |
| Celgene Corporation | $119.15 | 2019 | |
| Lilly USA, LLC | $107.03 | 2019-2024 | Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $87.30 | 2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $78.25 | 2019-2022 | |
| Genzyme Corporation | $71.26 | 2021-2022 | |
| Ucb, INC. | $42.22 | 2019-2023 | Bimzelx |
| Elekta, INC. | $34.91 | 2024 | Elekta Medical Linear Accelerator |
| E.R. Squibb & Sons, L.L.C. | $34.68 | 2023 | Sotyktu |
| Leo Pharma INC. | $32.14 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.69 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $19.17 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $17.89 | 2024 | |
| Sebela Pharmaceuticals INC. | $15.23 | 2019 | |
| Glenmark Therapeutics INC. | $5.00 | 2019 | |
| Organon LLC | $4.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Max listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.